Security
Lantheus Holdings, Inc. Common Stock · LNTH
LNTHNASDAQCommon stockCurrentCIK 1521036Updated Nov 12, 2026
Name history
Lantheus MI Holdings, Inc. · through May 23, 2014
LNTH price & chart
Loading TradingView…
NASDAQ:LNTH on TradingView ↗About the company
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
In the news
Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders ↗
Curium Announces Definitive Agreement to Merge with Lantheus ↗
Shareholders that lost money on Lantheus Holdings, Inc.(LNTH) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More News provided by Levi & Korsinsky, LLP Nov 07, 2025, 16:00 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 7, 2025 /PRNewswire/ -- Levi & K ↗
Recent filings
SCHEDULE 13D/A - filed by Lantheus Holdings, Inc. regarding Perspective Therapeutics, Inc.
Other Events
Items 8.01
SCHEDULE 13G/A - filed by FMR LLC regarding Lantheus Holdings, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders
Items 5.07
DEFA14A filing
Other Events
Items 8.01
DEFA14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 2,276,400,000Source | 2,049,630,000Source | 2,414,662,000Source | 2,116,077,000Source | 1,939,831,000Source | 2,346,587,000Source | 2,055,224,000Source | 1,831,334,000Source | 2,227,399,000Source | 1,980,340,000Source | 1,651,149,000Source | 1,321,258,000Source |
| Property, Plant and Equipment, NetUSD | 164,072,000Source | 169,512,000Source | 153,270,000Source | 157,726,000Source | 158,158,000Source | 157,563,000Source | 180,783,000Source | 150,090,000Source | 163,686,000Source | 176,798,000Source | 146,697,000Source | 122,166,000Source |
| GoodwillUSD | 240,328,000Source | 61,189,000Source | 239,050,000Source | 176,869,000Source | 61,189,000Source | 239,399,000Source | 61,189,000Source | 61,189,000Source | 239,517,000Source | 61,189,000Source | 61,189,000Source | 61,189,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 739,264,000Source | 173,606,000Source | 689,335,000Source | 359,946,000Source | 172,239,000Source | 706,058,000Source | 153,745,000Source | 142,054,000Source | 722,779,000Source | 161,761,000Source | 151,985,000Source | 315,285,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 382,006,000Source | 866,386,000Source | 593,298,000Source | 695,572,000Source | 757,018,000Source | 498,582,000Source | 938,533,000Source | 718,279,000Source | 359,121,000Source | 912,814,000Source | 713,656,000Source | 415,652,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 351,376,000Source | 329,336,000Source | 352,887,000Source | 336,579,000Source | 372,288,000Source | 355,666,000Source | 348,749,000Source | 337,389,000Source | 358,640,000Source | 321,258,000Source | 284,292,000Source | 213,397,000Source |
| Inventory, NetUSD | 62,040,000Source | 70,835,000Source | 57,551,000Source | 62,157,000Source | 70,516,000Source | 61,339,000Source | 69,126,000Source | 69,758,000Source | 64,674,000Source | 68,025,000Source | 64,029,000Source | 35,475,000Source |
| Assets, CurrentUSD | 925,091,000Source | 1,295,714,000Source | 1,027,059,000Source | 1,201,816,000Source | 1,231,146,000Source | 942,288,000Source | 1,423,780,000Source | 1,148,800,000Source | 899,964,000Source | 1,326,633,000Source | 1,085,819,000Source | 677,616,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 39,346,000Source | — | — | 42,541,000Source | — | — | 44,382,000Source | 30,975,000Source | 36,083,000Source | 45,325,000Source | 19,033,000Source |
| Other Assets, NoncurrentUSD | 53,721,000Source | 46,177,000Source | 59,719,000Source | 36,390,000Source | 49,491,000Source | 61,742,000Source | 36,467,000Source | 51,343,000Source | 50,044,000Source | 44,237,000Source | 55,261,000Source | 34,355,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,157,194,000Source | 869,922,000Source | 1,102,884,000Source | 949,294,000Source | 913,146,000Source | 1,134,299,000Source | 891,030,000Source | 885,794,000Source | 1,137,602,000Source | 892,329,000Source | 835,257,000Source | 874,111,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 718,000Source | 709,000Source | 725,000Source | 717,000Source | 708,000Source | 723,000Source | 716,000Source | 706,000Source | 718,000Source | 709,000Source | 699,000Source | 689,000Source |
| Retained Earnings (Accumulated Deficit)USD | 625,416,000Source | 457,735,000Source | 872,950,000Source | 597,645,000Source | 326,642,000Source | 797,921,000Source | 518,890,000Source | 264,569,000Source | 679,504,000Source | 445,945,000Source | 133,503,000Source | -193,158,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,665,000Source | -1,166,000Source | -2,166,000Source | -1,482,000Source | -1,210,000Source | -1,867,000Source | -1,758,000Source | -1,178,000Source | -1,307,000Source | -1,615,000Source | -1,037,000Source | -1,259,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,119,206,000Source | 1,179,708,000Source | 1,311,778,000Source | 1,166,783,000Source | 1,026,685,000Source | 1,212,288,000Source | 1,164,194,000Source | 945,540,000Source | 1,089,797,000Source | 1,088,011,000Source | 815,892,000Source | 447,147,000Source |
| Additional Paid in Capital, Common StockUSD | 871,193,000Source | 797,430,000Source | 917,707,000Source | 844,903,000Source | 775,545,000Source | 892,949,000Source | 821,346,000Source | 756,443,000Source | 888,320,000Source | 817,972,000Source | 757,727,000Source | 715,875,000Source |
| Liabilities and EquityUSD | 2,276,400,000Source | 2,049,630,000Source | 2,414,662,000Source | 2,116,077,000Source | 1,939,831,000Source | 2,346,587,000Source | 2,055,224,000Source | 1,831,334,000Source | 2,227,399,000Source | 1,980,340,000Source | 1,651,149,000Source | 1,321,258,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 346,838,000Source | 784,079,000Source | 335,677,000Source | 280,132,000Source | 263,285,000Source | 333,166,000Source | 248,002,000Source | 237,198,000Source | 333,419,000Source | 240,526,000Source | 187,350,000Source | 247,701,000Source |
| Operating Lease, Liability, CurrentUSD | — | 2,062,000Source | — | — | 2,094,000Source | — | — | 1,980,000Source | 3,804,000Source | 1,867,000Source | 1,904,000Source | 2,177,000Source |
| Accounts Payable, CurrentUSD | 66,296,000Source | 44,914,000Source | 48,109,000Source | 40,891,000Source | 49,774,000Source | 45,875,000Source | 44,874,000Source | 37,525,000Source | 42,906,000Source | 34,560,000Source | 41,189,000Source | 20,563,000Source |
| Operating Lease, Liability, NoncurrentUSD | 50,629,000Source | 53,915,000Source | 53,907,000Source | 47,851,000Source | 54,125,000Source | 55,345,000Source | 47,558,000Source | 54,124,000Source | 50,016,000Source | 53,185,000Source | 54,453,000Source | 25,442,000Source |
| Deferred Income Tax Liabilities, NetUSD | 55,078,000Source | — | 54,057,000Source | — | — | 53,508,000Source | — | — | 54,246,000Source | — | — | — |
| Other Liabilities, NoncurrentUSD | 116,180,000Source | 61,993,000Source | 91,534,000Source | 102,179,000Source | 63,543,000Source | 105,235,000Source | 58,190,000Source | 63,107,000Source | 107,866,000Source | 63,180,000Source | 63,321,000Source | 46,155,000Source |
| Additional Financial Items | ||||||||||||
| Long-term Debt, Excluding Current Maturities | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Long-term Debt, Current MaturitiesUSD | 871,000Source | 564,713,000Source | 697,000Source | 796,000Source | 868,000Source | 803,000Source | 747,000Source | 734,000Source | 738,000Source | 974,000Source | 823,000Source | 354,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 557,712,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 16,041,000Source | 21,198,000Source | 85,563,000Source | 76,393,000Source | 50,507,000Source | 29,262,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 2,232,000Source | 26,363,000Source | 17,888,000Source | 37,685,000Source | 68,637,000Source | 128,460,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -2,113,000Source | -278,000Source | 9,366,000Source | 2,670,000Source | 36,220,000Source | 7,508,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 190,000Source | 4,982,000Source | -2,492,000Source | -8,804,000Source | 17,189,000Source | 301,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 21,595,000Source | -30,029,000Source | -55,632,000Source | -48,016,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 125,127,000Source | 107,563,000Source | 390,141,000Source | 544,750,000Source | 305,260,000Source | 281,781,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 25,986,000Source | -63,718,000Source | -627,168,000Source | -226,015,000Source | 5,939,000Source | -276,547,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 15,695,000Source | 23,686,000Source | 26,338,000Source | 22,615,000Source | 14,394,000Source | 7,759,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | 300,017,000Source | 100,000,000Source | 0Source | 75,000,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -11,623,000Source | -18,219,000Source | -316,584,000Source | -118,536,000Source | -13,062,000Source | 311,691,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 216,000Source | 402,000Source | 1,110,000Source | 318,000Source | 717,000Source | 175,385,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 139,468,000Source | 25,728,000Source | -553,660,000Source | 199,201,000Source | 298,044,000Source | 316,590,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 383,704,000Source | 868,049,000Source | 595,015,000Source | 697,262,000Source | 500,294,000Source | 940,214,000Source | 360,826,000Source | 914,486,000Source | 715,285,000Source | 417,241,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 15,094,000Source | 15,094,000Source | 15,387,000Source | 5,064,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 69,037,000Source | 153,815,000Source | 151,579,000Source | 54,049,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -22,000Source | 102,000Source | -49,000Source | -998,000Source | -93,000Source | -335,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 24,501,000Source | 20,366,000Source | 20,007,000Source | 22,321,000Source | 16,041,000Source | 21,198,000Source | 85,563,000Source | 76,393,000Source | 50,507,000Source | 29,262,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 1,115,000Source | 1,115,000Source | 4,457,000Source | 4,296,000Source | 4,300,000Source | 1,249,000Source |
| Amortization of Intangible AssetsUSD | — | — | 14,600,000Source | 11,900,000Source | — | 8,000,000Source | 16,700,000Source | 8,000,000Source | 47,100,000Source | 43,800,000Source | 46,400,000Source | 33,200,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | — | — | — | — | — | — | — | 123,000Source | 494,000Source | 428,000Source | 373,000Source | 1,430,000Source |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | — | — | — | 22,683,000Source | 13,626,000Source | 70,098,000Source | 64,624,000Source | 60,043,000Source | 47,929,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 5,494,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | 1,160,000Source | 37,325,000Source | -9,536,000Source | 14,573,000Source | 14,905,000Source | -14,862,000Source | -8,617,000Source | -43,564,000Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | — | 14,905,000Source | -14,862,000Source | -8,617,000Source | -43,564,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -269,000Source | 46,000Source | -910,000Source | -342,000Source | 1,203,000Source | -78,000Source | -1,006,000Source | -733,000Source | -21,000Source | -256,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | 0Source | 0Source | 8,415,000Source | 51,789,000Source | 0Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 5,000,000Source | — | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | 0Source | 0Source | — | — | — | 0Source | 0Source | 8,415,000Source | 0Source | 0Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 5,494,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | -588,000Source |
| General and Administrative ExpenseUSD | — | — | 81,898,000Source | 40,516,000Source | 20,633,000Source | 66,515,000Source | 57,533,000Source | 56,816,000Source | 275,121,000Source | 193,689,000Source | 125,458,000Source | 133,584,000Source |
| GoodwillUSD | — | — | 240,328,000Source | 61,189,000Source | 239,050,000Source | 176,869,000Source | 239,399,000Source | 61,189,000Source | 239,517,000Source | 61,189,000Source | 61,189,000Source | 61,189,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 14,610,000Source | 45,025,000Source | 18,796,000Source | 25,762,000Source | 37,988,000Source | 23,584,000Source | 80,233,000Source | 118,535,000Source | 84,282,000Source | -1,348,000Source |
| InterestExpenseNonoperatingUSD | — | — | 4,950,000Source | 4,903,000Source | 4,915,000Source | 4,917,000Source | 4,864,000Source | 4,804,000Source | 19,749,000Source | 19,669,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 1,537,000Source | -1,378,000Source | 2,202,000Source | -904,000Source | 7,914,000Source | 7,145,000Source |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | 36,838,000Source | 19,638,000Source | 2,613,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 27,771,000Source | 131,093,000Source | 75,029,000Source | 78,755,000Source | 118,417,000Source | 72,945,000Source | 233,559,000Source | 312,442,000Source | 326,661,000Source | 28,067,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 27,771,000Source | 131,093,000Source | 75,029,000Source | 78,755,000Source | 118,417,000Source | 72,945,000Source | 233,559,000Source | 312,442,000Source | 326,661,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 2,556,000Source | 9,953,000Source | 7,862,000Source | 6,895,000Source | 5,710,000Source | 14,128,000Source | 31,326,000Source | 37,231,000Source | 66,320,000Source | -1,703,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 1,983,000Source | — | 3,450,000Source | 1,933,000Source | 1,375,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 557,750,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,697,000Source | 3,886,000Source | 7,154,000Source | 3,278,000Source | 3,816,000Source | 7,537,000Source |
| AssetAcquisitionContingentConsiderationLiability | — | — | — | — | — | —Source | — | — | — | — | — | — |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Gain (Loss) on Disposition of Business | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 384,014,000Source | 378,734,000Source | 388,180,000Source | 378,045,000Source | 377,333,000Source | 372,764,000Source | 1,541,609,000Source | 1,533,910,000Source | 1,296,429,000Source | 935,061,000Source |
| Cost of RevenueUSD | — | — | 161,648,000Source | 136,608,000Source | 146,325,000Source | 137,034,000Source | 146,411,000Source | 135,064,000Source | 599,657,000Source | 545,619,000Source | 586,886,000Source | 353,358,000Source |
| Operating Income (Loss)USD | — | — | 43,615,000Source | 133,743,000Source | 100,215,000Source | 87,966,000Source | 81,326,000Source | 102,067,000Source | 310,832,000Source | 456,979,000Source | 364,642,000Source | 36,195,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,556,000Source | 9,953,000Source | 7,862,000Source | 6,895,000Source | 5,710,000Source | 14,128,000Source | 31,326,000Source | 37,231,000Source | 66,320,000Source | -1,703,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 42,381,000Source | 176,118,000Source | 93,825,000Source | 104,517,000Source | 156,405,000Source | 96,529,000Source | 313,792,000Source | 430,977,000Source | 410,943,000Source | 26,719,000Source |
| Income Tax Expense (Benefit)USD | — | — | 14,610,000Source | 45,025,000Source | 18,796,000Source | 25,762,000Source | 37,988,000Source | 23,584,000Source | 80,233,000Source | 118,535,000Source | 84,282,000Source | -1,348,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 27,771,000Source | 131,093,000Source | 75,029,000Source | 78,755,000Source | 118,417,000Source | 72,945,000Source | 233,559,000Source | 312,442,000Source | 326,661,000Source | 28,067,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.41Source | 1.89Source | 1.15Source | 1.15Source | 1.83Source | 1.06Source | 3.46Source | 4.52Source | 4.79Source | 0.41Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.41Source | 1.79Source | 1.11Source | 1.12Source | 1.8Source | 1.02Source | 3.41Source | 4.36Source | 4.65Source | 0.4Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 67,230,000Source | 69,464,000Source | 65,160,000Source | 68,516,000Source | 64,736,000Source | 68,675,000Source | 67,489,000Source | 69,199,000Source | 68,266,000Source | 68,487,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 67,663,000Source | 73,065,000Source | 67,518,000Source | 70,312,000Source | 65,772,000Source | 71,461,000Source | 68,443,000Source | 71,651,000Source | 70,239,000Source | 70,671,000Source |
| Interest Expense (non-operating)USD | — | — | 4,950,000Source | 4,903,000Source | 4,915,000Source | 4,917,000Source | 4,864,000Source | 4,804,000Source | 19,749,000Source | 19,669,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 14,600,000Source | 11,900,000Source | — | 8,000,000Source | 16,700,000Source | 8,000,000Source | 47,100,000Source | 43,800,000Source | 46,400,000Source | 33,200,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 58,638,000Source | 148,564,000Source | 139,914,000Source | 46,668,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -269,000Source | 46,000Source | -910,000Source | -342,000Source | 1,203,000Source | -78,000Source | -1,006,000Source | -733,000Source | -21,000Source | -256,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 5,494,000Source |
| General and Administrative ExpenseUSD | — | — | 81,898,000Source | 40,516,000Source | 20,633,000Source | 66,515,000Source | 57,533,000Source | 56,816,000Source | 275,121,000Source | 193,689,000Source | 125,458,000Source | 133,584,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | — | — | 222,366,000Source | 242,126,000Source | 241,855,000Source | 241,011,000Source | 230,922,000Source | 237,700,000Source | 941,952,000Source | 988,291,000Source | 709,543,000Source | 581,703,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 320,265,000Source | 429,899,000Source | 410,326,000Source | 29,012,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 20,019,000Source | 7,185,000Source |
| Interest Income, OtherUSD | — | — | 3,623,000Source | 9,801,000Source | 6,259,000Source | 7,213,000Source | 4,969,000Source | 9,482,000Source | 23,391,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | — | 36,838,000Source | 19,638,000Source | 2,613,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 27,771,000Source | 131,093,000Source | 75,029,000Source | 78,755,000Source | 118,417,000Source | 72,945,000Source | 233,559,000Source | 312,442,000Source | 326,661,000Source | — |
| Research and Development ExpenseUSD | — | — | 48,025,000Source | 24,148,000Source | 38,202,000Source | 45,489,000Source | 39,379,000Source | 36,314,000Source | 177,308,000Source | 168,098,000Source | 77,707,000Source | 311,681,000Source |
| Selling and Marketing ExpenseUSD | — | — | 48,828,000Source | 43,719,000Source | 82,805,000Source | 41,041,000Source | 52,684,000Source | 42,503,000Source | 178,691,000Source | 177,940,000Source | 141,736,000Source | 100,243,000Source |
| Debt Securities, Gain (Loss) | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
lnth-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 Lantheus Reports Third Quarter 2026 Financial Results • Worldwide revenue of $389.9 million in the third quarter of 2026 • GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 • Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third quarter of 2025 • FDA approves TAUKLARIFY™ (florquinitau F-18 injection); an F-18-labeled tau PET imaging agent for the evaluation of adults with cognitive impairment being assess…
Read attachment ↗d168705dex991.htm · DEFA14A · 2026-08-13
Exhibit 99.1 Dear Valued Supplier, Recently we announced that Lantheus has signed a definitive agreement to be acquired by a wholly owned subsidiary of Curium, a leading global radiopharmaceutical company. You can read the full press release here. Curium has proven expertise in the development, manufacturing and supply of radiopharmaceuticals that improve the way cancer is diagnosed and treated. They operate one of the world’s most extensive nuclear medicine manufacturing and distribution net…
Read attachment ↗lnth-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Adjusted fully diluted earnings per share of $1.55, compared to $1.57 in the second quarter of 2025 • Announced on August 3, 2026 that it has entered into a definitive agreement to merge with Curium under which C…
Read attachment ↗d112214dex991.htm · DEFA14A · 2026-08-04
Exhibit 99.1 Hi everyone, Yesterday we shared a significant milestone for all of us - the announcement that Curium and Lantheus will combine. This merger will allow us to capitalise on our complementary strengths and accelerate delivery of leading diagnostic and therapeutic solutions for our patients worldwide. Congratulations to you all! Together, we are creating a business with deep and broad expertise, earned from decades of hard work, vision and respective industry leadership. With our co…
Read attachment ↗d120569dex991.htm · DEFA14A · 2026-08-03
Exhibit 99.1 All Employee Note To: All Lantheus Employees From: Mary Anne Heino Date: August 3, 2026 Subject: A Message from Mary Anne Heino: Lantheus Announces Definitive Agreement to be Acquired by Curium Dear Lantheus Colleagues, We’re pleased to share a major step forward; one made possible by the dedication and talent of all of you and the exceptional company we have built together. We just announced that Lantheus has signed a definitive agreement to be acquired by a wholly owned sub…
Read attachment ↗d120569dex992.htm · DEFA14A · 2026-08-03
Exhibit 99.2 Leader Toolkit + Email Cover Note Date: August 3, 2026 RE: Leader Toolkit for Lantheus’ Acquisition by Curium Leaders, Today marks a defining moment for Lantheus and the ultimate validation of what we have built over seven decades of innovation in radiopharmaceuticals. We announced that Lantheus has entered into a definitive agreement to be acquired by a wholly owned subsidiary of Curium, a leader in radiopharmaceuticals with deep nuclear medicine expertise. This transaction b…
Read attachment ↗